---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-103117"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:11:36.741301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs

## Summary
- FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.
- Cash, equivalents and ST investments $145.7M at YE2025 (up from $47.2M); cash runway into 2028.
- HWK-007 (PTK7) and HWK-016 (MUC16) ADCs both actively recruiting Phase 1 trials in lung, ovarian, endometrial cancers.
- HWK-206 IND submission for small-cell lung cancer and neuroendocrine tumors planned mid-2026; Phase 1 start Q3 2026.
- Margaret Dugan appointed CMO in December 2025.

## SEC filing metadata
- accession: 0001193125-26-103117
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/whwk-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-103117
- JSON: https://secwatch.observer/filing/0001193125-26-103117.json
- Plain text: https://secwatch.observer/filing/0001193125-26-103117.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the full-year ended December 31, 2025 results: net income $20.6 million.
  - Period: the full-year ended December 31, 2025
  - Net income: $20.6 million
  - Result: reported results
  source text: Net loss for the full-year ended December 31, 2025, was $20.6 million, as compared to $63.7 million for the same period in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the three months ended December 31, 2025 results: net income $23.3 million.
  - Period: the three months ended December 31, 2025
  - Net income: $23.3 million
  - Result: reported results
  source text: Net loss for the three months ended December 31, 2025, was $23.3 million as compared to $18.3 million for the three months ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.